Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study

被引：0
|
作者：
Steven R. Feldman
Nataliya Reznichenko
Grazyna Pulka
Külli Kingo
Fausto George Galdava
Joanna Berti
Roshan Sobierska
Eric Dias
Halimu N. Guenzi
Richard Hendrik Otto
Heimo Haliduola
机构：
[1] Wake Forest School of Medicine,
[2] The University of Southern Denmark,undefined
[3] Military Hospital (Military Unit A3309) of Military-Medical Clinical Center of Southern Region,undefined
[4] Centrum Medyczne All-Med,undefined
[5] Tartu University Hospital,undefined
[6] Scientific Research National Center of Dermatology and Venereology LLC,undefined
[7] Alvotech Swiss AG,undefined
[8] Alvotech Germany GmbH,undefined
[9] RK Statistics Ltd,undefined
来源：
BioDrugs | 2021年 / 35卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：735 / 748
页数：13
相关论文
共 50 条
  • [31] Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study
    Asahina, Akihiko
    Nakagawa, Hidemi
    Etoh, Takafumi
    Ohtsuki, Mamitaro
    JOURNAL OF DERMATOLOGY, 2010, 37 (04): : 299 - 310
  • [32] Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study
    Papp, K. A.
    Kaufmann, R.
    Thaci, D.
    Hu, C.
    Sutherland, D.
    Rohane, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 (03) : e376 - e383
  • [33] Randomized, Double-Blind, Phase 3 Study of Efficacy and Safety of ABP 501 Compared with Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis
    Cohen, Stanley B.
    Genovese, Mark C.
    Choy, Ernest H.
    Perez-Ruiz, Fernando
    Pablos, Jose L.
    Zhang, Nan
    Kaur, Primal
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [34] A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Efficacy, Safety and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis
    Wiland, Piotr
    Jeka, Slawomir
    Dokoupilova, Eva
    Miranda Limon, Juan Manuel
    Jauch-Lembach, Julia
    Thakur, Anjali
    Haliduola, Halimuniyazi
    Gaylis, Norman B.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [35] Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial
    Reich, Kristian
    Thyssen, Jacob P.
    Blauvelt, Andrew
    Eyerich, Kilian
    Soong, Weily
    Rice, Zakiya P.
    Hong, H. Chih-ho
    Katoh, Norito
    Valenzuela, Fernando
    DiBonaventura, Marco
    Bratt, Tamara A.
    Zhang, Fan
    Clibborn, Claire
    Rojo, Ricardo
    Valdez, Hernan
    Kerkmann, Urs
    LANCET, 2022, 400 (10348): : 273 - 282
  • [36] Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study
    Papp, Kim
    Bachelez, Herve
    Costanzo, Antonio
    Foley, Peter
    Gooderham, Melinda
    Kaur, Primal
    Narbutt, Joanna
    Philipp, Sandra
    Spelman, Lynda
    Weglowska, Jolanta
    Zhang, Nan
    Strober, Bruce
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : 1093 - 1102
  • [37] Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
    Reich, Kristian
    Papp, Kim A.
    Blauvelt, Andrew
    Langley, Richard G.
    Armstrong, April
    Warren, Richard B.
    Gordon, Kenneth B.
    Merola, Joseph F.
    Okubo, Yukari
    Madden, Cynthia
    Wang, Maggie
    Cioffi, Christopher
    Vanvoorden, Veerle
    Lebwohl, Mark
    LANCET, 2021, 397 (10273): : 487 - 498
  • [38] Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: A randomized, double-blind, placebo-controlled phase 3 trial
    Yan, Kexiang
    Li, Fuqiu
    Bi, Xiaodong
    Han, Ling
    Zhang, Zhenghua
    Chen, Rixin
    Li, Yuye
    Zhang, Litao
    Wang, Xiaohua
    Li, Linfeng
    Lu, Jianyun
    Xu, Ai'e
    Yang, Sen
    Lu, Yan
    Sun, Jianfang
    Li, Zhiming
    Zhu, Xiaohong
    Jiang, Meiying
    Zhang, Siping
    Wang, Wenqing
    Li, Yanling
    Meng, Zudong
    Li, Hongyi
    Mou, Kuanhou
    Han, Xiuping
    Li, Shanshan
    Chen, Aijun
    Li, Xin
    Liu, Donghua
    Zhang, Chunlei
    Ji, Chao
    Wang, Yu
    Cheng, Hao
    Cui, Xiaojing
    Yao, Xiaoyan
    Bai, Xiaoyan
    Dong, Guangchao
    Xu, Jinhua
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2025, 92 (01) : 92 - 99
  • [39] A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis
    Papp, Kim
    Balser, Sigrid
    Nopora, Katrin
    Rewerski, Piotr
    Freudensprung, Brigitte
    Trieb, Michael
    ADVANCES IN THERAPY, 2025, : 2135 - 2149
  • [40] Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study
    Landis, Megan N.
    Smith, Stacy R.
    Berstein, Gabriel
    Fetterly, Gerald
    Ghosh, Pranab
    Feng, Gang
    Pradhan, Vivek
    Aggarwal, Sudeepta
    Banfield, Christopher
    Peeva, Elena
    Vincent, Michael S.
    Beebe, Jean S.
    Tarabar, Sanela
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 189 (01) : 33 - 41
12345